The EPS projection of LeMaitre Vascular, Inc. (NASDAQ:LMAT) for quarter ended 2016-09-30 is $0.12. Last week, the EPS forecast was $0.12 against target of $0.12, a month earlier. Two months ago, this estimate was $0.12 versus forecast of $0.12 three months earlier, implying a deviation of 0%.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) stated that 18 days ago, its stock price was positively revised 2 times while negative revisions were 0.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 2, 2, and 2, correspondingly.
EPS estimate downgrade for LeMaitre Vascular, Inc. (NASDAQ:LMAT) in the preceding 30, 120, 60 and 90 days were 0, 0, 0, and 0, correspondingly.
LeMaitre Vascular, Inc. (NASDAQ:LMAT) EPS target for the quarter closed 1 was $0.12, based on 3 recommendations. As reported on 2016-05-02 the EPS was $0.11. The change was $0.01, implying a percentage deviation of 10%. The projections showed a standard deviation of 0.
Quarterly Sales Estimates
LeMaitre Vascular, Inc. (NASDAQ:LMAT) yearly sales prediction for the fiscal 2016 stands at $22.716 and the median estimate is at $22.76. Almost 3 analysts issued sales target.
Highest sales target is $22.8 while the lowest target is $22.59 showing standard deviation of 0.111%.
As many as 3 analysts have sales targets revised upside while 3 reduced sales estimates, implying a deviation of 0%.
Last month, 3 revised sales number projection on upside while 3 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 3 hiked sales target and 3 reduced sales forecast. LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced that the deviation in forecast was 1.774%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...